Skip to main content
رجوع
CRSP logo

CRISPR Therapeutics AG

جودة البيانات: 100%
CRSP
NASDAQ Healthcare Biotechnology
KWD 46.88
▲ KWD 0.64 (1.38%)
القيمة السوقية: 4.50B
نطاق اليوم
KWD 46.40 KWD 47.84
نطاق 52 أسبوعًا
KWD 30.04 KWD 78.48
حجم التداول
1,441,615
متوسط 50 يوم / 200 يوم
KWD 53.33 / KWD 55.91
الإغلاق السابق
KWD 46.24

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -7.7 0.4
P/B 2.3 2.9
ROE % -30.2 3.8
Net Margin % -16569.8 3.9
Rev Growth 5Y % -75.1 10.0
D/E 0.2 0.2

النقاط الرئيسية

Revenue declined -75.10% annually over 5 years
Debt/Equity of 0.21 — conservative balance sheet
Negative free cash flow of -345.93M
Revenue growth is decelerating — 1Y growth trails 5Y average by 14.87%

النمو

Revenue Growth (5Y)
-75.10%
Revenue (1Y)-89.97%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-30.18%
ROIC-18.40%
Net Margin-16569.77%
Op. Margin-16191.40%

الأمان

Debt / Equity
0.21
Current Ratio13.32
Interest Coverage0.00

التقييم

P/E Ratio
-7.74
P/B Ratio2.34
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -89.97% Revenue Growth (3Y) -90.26%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -75.10% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 3.51M Net Income (TTM) -581.60M
ROE -30.18% ROA -25.67%
Gross Margin -6537.01% Operating Margin -16191.40%
Net Margin -16569.77% Free Cash Flow (TTM) -345.93M
ROIC -18.40% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.21 Current Ratio 13.32
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -7.74 P/B Ratio 2.34
P/S Ratio 1281.99 PEG Ratio -0.17
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 4.50B Enterprise Value 4.54B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3.51M 35.00M 370.00M 436,000.0 913.08M
Net Income -581.60M -366.25M -153.61M -650.18M 377.66M
EPS (Diluted) -6.47 -4.34 -1.94 -8.36 4.70
Gross Profit -229.45M -75.25M 239.75M -109.81M 811.90M
Operating Income -568.32M -466.57M -222.54M -673.16M 373.53M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2.27B 2.24B 2.23B 2.24B 2.75B
Total Liabilities 343.43M 309.95M 346.77M 367.58M 352.42M
Shareholders' Equity 1.92B 1.93B 1.88B 1.88B 2.40B
Total Debt 394.91M 223.69M 238.63M 244.02M 225.03M
Cash & Equivalents 355.19M 298.26M 389.48M 211.89M 923.03M
Current Assets 1.99B 1.94B 1.91B 1.85B 2.42B
Current Liabilities 149.12M 87.78M 108.79M 121.11M 119.88M